article thumbnail

Data integrity considerations in Pharma and Life Sciences

European Pharmaceutical Review

Life science companies are increasingly using advanced technologies like artificial intelligence (AI), machine learning (ML) and blockchain to improve data quality and integrity by detecting anomalies in data and establishing tamper-proof audit trails for all data-related activities Data governance. Training and education.

article thumbnail

How do Healthcare AI Developers (and Buyers) Stay Ahead of the Regulatory Curve?

Nixon Gwilt Law

Its three separate Rules (Security, Privacy, and Breach) impose a variety of security controls, documentation, governance, and notice requirements on custodians of protected health information (PHI). The HTI-1 Final Rule is an AI disclosure and governance rule published by the US Department of Health and Human Services (HHS).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Training and development. Staff development and training programmes were largely on pause during the pandemic. However, demand for training has risen significantly since the start of this year as restrictions ease around the world. Harness technology. Embrace mobile learning.

article thumbnail

The Future of Medical Sales Careers: Trends, Challenges, and Opportunities

Rep-Lite

Regulatory Changes and Compliance Challenges Navigating the intricacies of healthcare sales involves staying attuned to the ever-evolving regulatory framework that governs the industry. Don’t get it wrong, these are all aimed at ensuring patient safety, transparency, and ethical standards.

article thumbnail

Why Is FDA Issuing Fewer Marketing Violation Letters?

Pharma Marketing Network

As new healthcare challenges arise and the pharmaceutical landscape evolves, the FDA may be allocating its resources to focus on other pressing issues, such as drug approvals, monitoring emerging health threats, and enhancing drug safety.

article thumbnail

Generative AI’s potential to speed delivery of improved patient outcomes

Clarivate

Regulatory asymmetry: Laws governing generative AI vary widely across markets and are evolving rapidly as regulators scramble to address this emerging technology. Predicting safety and efficacy by using large language models to identify relevant documents and ways to optimize existing solutions. Who owns the models?

article thumbnail

2022 WHO Biosimilar Guideline improves access, IGBA says

European Pharmaceutical Review

“This paper highlights how the revised 2022 WHO Biosimilars Guideline provides Clarity, Consistency and Confidence in state-of-the-art regulatory science for biosimilar medicines based on… experience and over 1 million patient-treatment years of safety data in Europe alone,” explained Julie Maréchal-Jamil, Co-Chair of the Biosimilars Committee. “We